Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. <i>Curr. Oncol.</i> 2022, <i>29</i>, 9891–9895”
We appreciate the opportunity to respond to the comment [...]
Main Authors: | Daniel Rayson, Sonal Gandhi, Anil A. Joy, Christine Brezden-Masley, Karen A. Gelmon, Sandeep Sehdev, David Cescon, Stephen Chia |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-05-01
|
Series: | Current Oncology |
Subjects: | |
Online Access: | https://www.mdpi.com/1718-7729/30/5/381 |
Similar Items
-
The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. <i>Curr. Oncol.</i> 2022, <i>29</i>, 9891–9895
by: Maureen Trudeau, et al.
Published: (2023-05-01) -
Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain
by: Daniel Rayson, et al.
Published: (2022-12-01) -
Correction: Ratnayake et al. Assessment of Breast Cancer Surgery in Manitoba: A Descriptive Study. <i>Curr. Oncol.</i> 2021, <i>28</i>, 581–592
by: Iresha Ratnayake, et al.
Published: (2021-07-01) -
Beyond the Mosaic: Justin Trudeau and the Postnational Chimera
by: Thibault Biscahie
Published: (2019-10-01) -
黄丽松与南洋大学 = Rayson Huang and Nanyang University
by: 王培青 Ong, Pei Ching
Published: (2011)